These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 33784797)

  • 21. Glycyrrhizin Alleviates Nonalcoholic Steatohepatitis via Modulating Bile Acids and Meta-Inflammation.
    Yan T; Wang H; Cao L; Wang Q; Takahashi S; Yagai T; Li G; Krausz KW; Wang G; Gonzalez FJ; Hao H
    Drug Metab Dispos; 2018 Sep; 46(9):1310-1319. PubMed ID: 29959134
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Calycosin attenuates triglyceride accumulation and hepatic fibrosis in murine model of non-alcoholic steatohepatitis via activating farnesoid X receptor.
    Duan X; Meng Q; Wang C; Liu Z; Liu Q; Sun H; Sun P; Yang X; Huo X; Peng J; Liu K
    Phytomedicine; 2017 Feb; 25():83-92. PubMed ID: 28190475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet.
    Somm E; Montandon SA; Loizides-Mangold U; Gaïa N; Lazarevic V; De Vito C; Perroud E; Bochaton-Piallat ML; Dibner C; Schrenzel J; Jornayvaz FR
    Transl Res; 2021 Jan; 227():75-88. PubMed ID: 32711187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis.
    Venetsanaki V; Karabouta Z; Polyzos SA
    Eur J Pharmacol; 2019 Nov; 863():172661. PubMed ID: 31536725
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Carbon tetrachloride (CCl
    Zhang G; Wang X; Chung TY; Ye W; Hodge L; Zhang L; Chng K; Xiao YF; Wang YJ
    BMC Gastroenterol; 2020 Oct; 20(1):339. PubMed ID: 33059584
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FXR agonists INT-787 and OCA increase RECK and inhibit liver steatosis and inflammation in diet-induced ob/ob mouse model of NASH.
    Di Pasqua LG; Cagna M; Palladini G; Croce AC; Cadamuro M; Fabris L; Perlini S; Adorini L; Ferrigno A; Vairetti M
    Liver Int; 2024 Jan; 44(1):214-227. PubMed ID: 37904642
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chicoric acid attenuate a nonalcoholic steatohepatitis by inhibiting key regulators of lipid metabolism, fibrosis, oxidation, and inflammation in mice with methionine and choline deficiency.
    Kim M; Yoo G; Randy A; Kim HS; Nho CW
    Mol Nutr Food Res; 2017 May; 61(5):. PubMed ID: 27981809
    [TBL] [Abstract][Full Text] [Related]  

  • 28. INT-767 improves histopathological features in a diet-induced
    Roth JD; Feigh M; Veidal SS; Fensholdt LK; Rigbolt KT; Hansen HH; Chen LC; Petitjean M; Friley W; Vrang N; Jelsing J; Young M
    World J Gastroenterol; 2018 Jan; 24(2):195-210. PubMed ID: 29375205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fucoxanthin inhibits hepatic oxidative stress, inflammation, and fibrosis in diet-induced nonalcoholic steatohepatitis model mice.
    Takatani N; Kono Y; Beppu F; Okamatsu-Ogura Y; Yamano Y; Miyashita K; Hosokawa M
    Biochem Biophys Res Commun; 2020 Jul; 528(2):305-310. PubMed ID: 32475638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Yellow loosestrife (Lysimachia vulgaris var. davurica) ameliorates liver fibrosis in db/db mice with methionine- and choline-deficient diet-induced nonalcoholic steatohepatitis.
    Son YJ; Jung DS; Shin JM; Kim M; Yoo G; Nho CW
    BMC Complement Med Ther; 2021 Jan; 21(1):44. PubMed ID: 33494735
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A dual farnesoid X receptor/soluble epoxide hydrolase modulator treats non-alcoholic steatohepatitis in mice.
    Hye Khan MA; Schmidt J; Stavniichuk A; Imig JD; Merk D
    Biochem Pharmacol; 2019 Aug; 166():212-221. PubMed ID: 31129048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Obeticholic acid for the treatment of nonalcoholic steatohepatitis.
    Shah RA; Kowdley KV
    Expert Rev Gastroenterol Hepatol; 2020 May; 14(5):311-321. PubMed ID: 32241197
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Obeticholic acid protects against carbon tetrachloride-induced acute liver injury and inflammation.
    Zhang DG; Zhang C; Wang JX; Wang BW; Wang H; Zhang ZH; Chen YH; Lu Y; Tao L; Wang JQ; Chen X; Xu DX
    Toxicol Appl Pharmacol; 2017 Jan; 314():39-47. PubMed ID: 27865854
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nomilin and its analogue obacunone alleviate NASH and hepatic fibrosis in mice via enhancing antioxidant and anti-inflammation capacity.
    Han Y; Luo L; Li H; Zhang L; Yan Y; Fang M; Yu J; Gao X; Liu Y; Huang C; Fan S
    Biofactors; 2023; 49(6):1189-1204. PubMed ID: 37401768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activation of AMPK by triptolide alleviates nonalcoholic fatty liver disease by improving hepatic lipid metabolism, inflammation and fibrosis.
    Huang R; Guo F; Li Y; Liang Y; Li G; Fu P; Ma L
    Phytomedicine; 2021 Nov; 92():153739. PubMed ID: 34592488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Baicalin attenuates non-alcoholic steatohepatitis by suppressing key regulators of lipid metabolism, inflammation and fibrosis in mice.
    Zhang J; Zhang H; Deng X; Zhang N; Liu B; Xin S; Li G; Xu K
    Life Sci; 2018 Jan; 192():46-54. PubMed ID: 29158052
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis.
    Adorini L; Pruzanski M; Shapiro D
    Drug Discov Today; 2012 Sep; 17(17-18):988-97. PubMed ID: 22652341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trans-anethole attenuates diet-induced nonalcoholic steatohepatitis through suppressing TGF-β-mediated fibrosis.
    Zhang C; Zhang B; Chen A; Yin Q; Wang H
    Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101833. PubMed ID: 34785385
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Obeticholic acid inhibits hepatic fatty acid uptake independent of FXR in mouse.
    Lin C; Yu B; Liu X; Chen L; Zhang Z; Ye W; Zhong H; Bai W; Yang Y; Nie B
    Biomed Pharmacother; 2022 Jun; 150():112984. PubMed ID: 35447541
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis.
    Li J; Liu M; Li Y; Sun DD; Shu Z; Tan Q; Guo S; Xie R; Gao L; Ru H; Zang Y; Liu H; Li J; Zhou Y
    J Med Chem; 2020 Nov; 63(21):12748-12772. PubMed ID: 32991173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.